@article{32b7ebc57d7a4efba56d5e9b0b427d70,
title = "Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring",
abstract = "While the majority of enzalutamide-treated patients with nonmetastatic castration-resistant prostate cancer in PROSPER had some increase from nadir in prostate-specific antigen at the time of radiographic progression, the median absolute increase was less than the Prostate Cancer Working Group 2 threshold of 2 ng/mL.",
keywords = "Enzalutamide, Nonmetastatic castration-resistant prostate cancer, Prostate Cancer Working Group 2, Prostate-specific antigen progression",
author = "Fred Saad and Sternberg, {Cora N.} and Eleni Efstathiou and Karim Fizazi and Katharina Modelska and Xun Lin and Jennifer Sugg and Joyce Steinberg and Bettina Noerby and Shore, {Neal D.} and Maha Hussain",
note = "Funding Information: Financial disclosures: Fred Saad certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Fred Saad has served as a consultant for Astellas Pharma, Janssen Oncology, Sanofi, and AstraZeneca/MedImmune; has received honoraria from Astellas Pharma, Janssen Oncology, Sanofi, Bayer, and AstraZeneca; and has received institutional funding from Astellas Pharma, Bayer, Janssen Oncology, Sanofi, and AstraZeneca. Cora N. Sternberg has served as a consultant for Janssen-Cilag, Astellas Pharma, Sanofi-Genzyme, Novartis, Bayer, Pfizer, Merck, Merck Sharp & Dohme, and AstraZeneca; and has received prior institutional funding from Cougar Biotechnology (now Janssen), Medivation (now Pfizer), Clovis Oncology, and Roche-Genentech. Eleni Efstathiou has received honoraria from Janssen-Cilag, Sanofi, and Takeda; has served as a consultant for Janssen-Cilag, Sanofi, Astellas Pharma, Bayer, AstraZeneca, Merck Sharp & Dohme, Innocrin Pharma, Takeda, and Tolmar; has been a member of the speakers{\textquoteright} bureau for Janssen-Cilag; and has received research funding from Janssen-Cilag, Sanofi, and Astellas Pharma. Karim Fizazi has served as a consultant for Janssen Oncology, Bayer, Astellas Pharma, Sanofi, Orion Pharma GmbH, Curevac, AstraZeneca, ESSA, Roche/Genentech, Clovis Oncology, and Amgen; has received money for travel/accommodation expenses from Amgen; and has received honoraria from Janssen, Sanofi, Astellas Pharma, and Merck. Katharina Modelska is an employee of Pfizer Inc., with stock ownership in Pfizer Inc. Xun Lin is an employee of Pfizer Inc., with stock ownership in Pfizer Inc. Jennifer Sugg is an employee of Astellas Pharma, Inc., with stock ownership in AstraZeneca. Joyce Steinberg is an employee of Astellas Pharma, Inc. and has an immediate family member with stock ownership in Amgen. Bettina Noerby has received honoraria from Ferring and Amgen. Neal D. Shore has received grant support, and served as a consultant for AbbVie, Amgen, Astellas, Pharma, Bayer, Dendreon Pharmaceuticals, Ferring Pharmaceuticals, Janssen Oncology, Pfizer, Sanofi-Genzyme, and Tolmar Pharmaceuticals. Maha Hussain has served as a consultant for AstraZeneca, Pfizer Inc., and Bayer; has received honoraria and/or travel expenses from Genentech, Sanofi Genzyme, Research to Practice, Aptitude Health, Epics, Astellas, and PER; and has received institutional research funding from AstraZeneca, Bayer, Genentech, and Pfizer Inc. Publisher Copyright: {\textcopyright} 2020 The Authors",
year = "2020",
month = dec,
doi = "10.1016/j.eururo.2020.08.025",
language = "English (US)",
volume = "78",
pages = "847--853",
journal = "European urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "6",
}
